Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 136

1.

Critical requirement for Stat5 in a mouse model of polycythemia vera.

Yan D, Hutchison RE, Mohi G.

Blood. 2012 Apr 12;119(15):3539-49. doi: 10.1182/blood-2011-03-345215. Epub 2011 Dec 5.

2.

Conditional expression of heterozygous or homozygous Jak2V617F from its endogenous promoter induces a polycythemia vera-like disease.

Akada H, Yan D, Zou H, Fiering S, Hutchison RE, Mohi MG.

Blood. 2010 Apr 29;115(17):3589-97. doi: 10.1182/blood-2009-04-215848. Epub 2010 Mar 2.

3.

Essential role for Stat5a/b in myeloproliferative neoplasms induced by BCR-ABL1 and JAK2(V617F) in mice.

Walz C, Ahmed W, Lazarides K, Betancur M, Patel N, Hennighausen L, Zaleskas VM, Van Etten RA.

Blood. 2012 Apr 12;119(15):3550-60. doi: 10.1182/blood-2011-12-397554. Epub 2012 Jan 10.

4.

Expression of Jak2V617F causes a polycythemia vera-like disease with associated myelofibrosis in a murine bone marrow transplant model.

Wernig G, Mercher T, Okabe R, Levine RL, Lee BH, Gilliland DG.

Blood. 2006 Jun 1;107(11):4274-81. Epub 2006 Feb 14.

5.

The JAK2V617F allele burden and STAT3- and STAT5 phosphorylation in myeloproliferative neoplasms: early prefibrotic myelofibrosis compared with essential thrombocythemia, polycythemia vera and myelofibrosis.

Risum M, Madelung A, Bondo H, Bzorek M, Kristensen MH, Stamp IM, Hasselbalch HC.

APMIS. 2011 Aug;119(8):498-504. doi: 10.1111/j.1600-0463.2011.02754.x. Epub 2011 Apr 17.

PMID:
21749449
6.

Distinct roles for long-term hematopoietic stem cells and erythroid precursor cells in a murine model of Jak2V617F-mediated polycythemia vera.

Mullally A, Poveromo L, Schneider RK, Al-Shahrour F, Lane SW, Ebert BL.

Blood. 2012 Jul 5;120(1):166-72. doi: 10.1182/blood-2012-01-402396. Epub 2012 May 24.

7.

Depletion of Jak2V617F myeloproliferative neoplasm-propagating stem cells by interferon-α in a murine model of polycythemia vera.

Mullally A, Bruedigam C, Poveromo L, Heidel FH, Purdon A, Vu T, Austin R, Heckl D, Breyfogle LJ, Kuhn CP, Kalaitzidis D, Armstrong SA, Williams DA, Hill GR, Ebert BL, Lane SW.

Blood. 2013 May 2;121(18):3692-702. doi: 10.1182/blood-2012-05-432989. Epub 2013 Mar 13.

8.

Myeloproliferative neoplasm induced by constitutive expression of JAK2V617F in knock-in mice.

Marty C, Lacout C, Martin A, Hasan S, Jacquot S, Birling MC, Vainchenker W, Villeval JL.

Blood. 2010 Aug 5;116(5):783-7. doi: 10.1182/blood-2009-12-257063. Epub 2010 May 14.

9.

Selective inhibition of JAK2-driven erythroid differentiation of polycythemia vera progenitors.

Geron I, Abrahamsson AE, Barroga CF, Kavalerchik E, Gotlib J, Hood JD, Durocher J, Mak CC, Noronha G, Soll RM, Tefferi A, Kaushansky K, Jamieson CH.

Cancer Cell. 2008 Apr;13(4):321-30. doi: 10.1016/j.ccr.2008.02.017.

10.

[JAK2V617F mutation and p-STAT5 protein expression in peripheral blood cells of patients with myeloproliferative neoplasm and their relations with clinical features].

Chen YX, Li Y, Zhang LY, Liu X, Shan NN.

Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2012 Dec;20(6):1398-404. Chinese.

PMID:
23257441
11.

Efficacy of vorinostat in a murine model of polycythemia vera.

Akada H, Akada S, Gajra A, Bair A, Graziano S, Hutchison RE, Mohi G.

Blood. 2012 Apr 19;119(16):3779-89. doi: 10.1182/blood-2011-02-336743. Epub 2012 Mar 9.

12.

Determination of accuracy of polycythemia vera diagnoses and use of the JAK2V617F test in the diagnostic scheme.

Roda P, Ferrari A, Tang X, Erlich P, Eisenhower C, Patel MD, Irvin-Barnwell EA.

Ann Hematol. 2014 Sep;93(9):1467-72. doi: 10.1007/s00277-014-2068-2. Epub 2014 Apr 1.

PMID:
24687383
13.

Distinct clinical phenotypes associated with JAK2V617F reflect differential STAT1 signaling.

Chen E, Beer PA, Godfrey AL, Ortmann CA, Li J, Costa-Pereira AP, Ingle CE, Dermitzakis ET, Campbell PJ, Green AR.

Cancer Cell. 2010 Nov 16;18(5):524-35. doi: 10.1016/j.ccr.2010.10.013.

14.

Molecular pathogenesis and therapy of polycythemia induced in mice by JAK2 V617F.

Zaleskas VM, Krause DS, Lazarides K, Patel N, Hu Y, Li S, Van Etten RA.

PLoS One. 2006 Dec 20;1:e18.

15.

Tyrosine 201 is required for constitutive activation of JAK2V617F and efficient induction of myeloproliferative disease in mice.

Yan D, Hutchison RE, Mohi G.

Blood. 2012 Aug 30;120(9):1888-98. doi: 10.1182/blood-2011-09-380808. Epub 2012 Jul 26.

16.

JAK2V617F homozygosity drives a phenotypic switch in myeloproliferative neoplasms, but is insufficient to sustain disease.

Li J, Kent DG, Godfrey AL, Manning H, Nangalia J, Aziz A, Chen E, Saeb-Parsy K, Fink J, Sneade R, Hamilton TL, Pask DC, Silber Y, Zhao X, Ghevaert C, Liu P, Green AR.

Blood. 2014 May 15;123(20):3139-51. doi: 10.1182/blood-2013-06-510222. Epub 2014 Apr 1.

17.

Impact of JAK2V617F Mutation Burden on Disease Phenotype in Chinese Patients with JAK2V617F-positive Polycythemia Vera (PV) and Essential thrombocythemia (ET).

Zhao S, Zhang X, Xu Y, Feng Y, Sheng W, Cen J, Wu D, Han Y.

Int J Med Sci. 2016 Jan 25;13(1):85-91. doi: 10.7150/ijms.10539. eCollection 2016.

18.

Current diagnostic criteria for the chronic myeloproliferative disorders (MPD) essential thrombocythemia (ET), polycythemia vera (PV) and chronic idiopathic myelofibrosis (CIMF).

Michiels JJ, Bernema Z, Van Bockstaele D, De Raeve H, Schroyens W.

Pathol Biol (Paris). 2007 Mar;55(2):92-104. Epub 2006 Aug 21. Review.

PMID:
16919893
19.

Physiological Jak2V617F expression causes a lethal myeloproliferative neoplasm with differential effects on hematopoietic stem and progenitor cells.

Mullally A, Lane SW, Ball B, Megerdichian C, Okabe R, Al-Shahrour F, Paktinat M, Haydu JE, Housman E, Lord AM, Wernig G, Kharas MG, Mercher T, Kutok JL, Gilliland DG, Ebert BL.

Cancer Cell. 2010 Jun 15;17(6):584-96. doi: 10.1016/j.ccr.2010.05.015.

20.

pSTAT5 and ERK exhibit different expression in myeloproliferative neoplasms.

Wiśniewska-Chudy E, Szylberg Ł, Dworacki G, Mizera-Nyczak E, Marszałek A.

Oncol Rep. 2017 Apr;37(4):2295-2307. doi: 10.3892/or.2017.5476. Epub 2017 Feb 24.

PMID:
28260027

Supplemental Content

Support Center